Myasthenia Gravis – Pipeline Review, H1 2019: Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Myasthenia
Gravis – Pipeline Review, H1 2019”
drug pipelines has been
added to ResearchAndMarkets.com’s offering.

Myasthenia Gravis – Pipeline Review, H1 2019 provides
comprehensive information on the therapeutics under development for
Myasthenia Gravis (Immunology), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases. The Myasthenia Gravis (Immunology) pipeline
guide also reviews of key players involved in therapeutic development
for Myasthenia Gravis and features dormant and discontinued projects.

The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3,
6, 5, 15 and 1 respectively. Similarly, the Universities portfolio in
Phase II and Preclinical stages comprises 1 and 1 molecules,
respectively.

Myasthenia Gravis (Immunology) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic
    landscape of Myasthenia Gravis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Myasthenia Gravis
    (Immunology) by companies and universities/research institutes based
    on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of
    development ranging from pre-registration till discovery and
    undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline
    products which comprise, product description, descriptive licensing
    and collaboration details, R&D brief, MoA & other developmental
    activities.
  • The pipeline guide reviews key companies involved in Myasthenia Gravis
    (Immunology) therapeutics and enlists all their major and minor
    projects.
  • The pipeline guide evaluates Myasthenia Gravis (Immunology)
    therapeutics based on mechanism of action (MoA), drug target, route of
    administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued
    pipeline projects.
  • The pipeline guide reviews latest news related to pipeline
    therapeutics for Myasthenia Gravis (Immunology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and
    insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio
    and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under
    development for Myasthenia Gravis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of
    leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players
    and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding
    Myasthenia Gravis (Immunology) pipeline depth and focus of Indication
    therapeutics.
  • Develop and design in-licensing and out-licensing strategies by
    identifying prospective partners with the most attractive projects to
    enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects
    and understand from the know-how what drove them from pipeline.

Key Topics Covered

  1. Introduction
  2. Myasthenia Gravis – Overview
  3. Myasthenia Gravis – Therapeutics Development
  4. Myasthenia Gravis – Therapeutics Assessment
  5. Myasthenia Gravis – Companies Involved in Therapeutics Development
  6. Myasthenia Gravis – Drug Profiles
  7. Myasthenia Gravis – Dormant Projects
  8. Myasthenia Gravis – Discontinued Products
  9. Myasthenia Gravis – Product Development Milestones
  10. Appendix

Companies Mentioned

  • Akari Therapeutics PLC
  • Alexion Pharmaceuticals Inc.
  • Alpha Cancer Technologies Inc.
  • Argenx SE
  • BioMarin Pharmaceutical Inc.
  • Bristol-Myers Squibb Co.
  • CuraVac Inc.
  • Grifols S.A.
  • GT Biopharma Inc.
  • HanAll Biopharma Co. Ltd.
  • Momenta Pharmaceuticals Inc.
  • Neurotune AG
  • Novartis AG
  • Pfizer Inc.
  • Protalex Inc.
  • RA Pharmaceuticals Inc.
  • Toleranzia AB
  • Tolerion Inc.
  • UCB S.A.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/dtvrq1

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs